Berry Oncology, a member company of China’s Berry Genomics, raised $99.15 million in a Series B1 round of financing to double down on developing genetic testing solutions for cancer screening.
China Merchants Capital, a joint venture (JV) between state-owned China Merchants Group and Asia’s warehouse operator GLP, led the new round, according to a statement on Wednesday.
